Drug Patents owned by Siga Technologies
1. List of Tpoxx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 4 months from now) | |
| US9339466 | SIGA TECHNOLOGIES | Polymorphic forms of ST-246 and methods of preparation |
Mar, 2031
(8 years from now) | |
| CN101702904A | SIGA TECHNOLOGIES | Chemicals, Compositions, And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases |
Aug, 2015
(7 years ago) | |
| EP1638938A2 | SIGA TECHNOLOGIES | Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases |
Jun, 2024
(1 year, 4 months from now) | |
| EP1638938A4 | SIGA TECHNOLOGIES | Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases |
Jun, 2024
(1 year, 4 months from now) | |
| EP1638938B1 | SIGA TECHNOLOGIES | Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases |
Jun, 2024
(1 year, 4 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 4 months from now) | |
| US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 4 months from now) | |
| US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(4 years from now) | |
| US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(8 years from now) | |
| US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(8 years from now) | |
| US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(8 years from now) | |
| US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity (ODE) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 13 July, 2018
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg; Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic